Survivin (BIRC5) Gene Polymorphism (rs9904341) Is Associated with Cancer Risk: A Meta-Analysis.

Q2 Medicine

Asian Pacific Journal of Cancer Prevention Pub Date : 2025-05-01 DOI:10.31557/APJCP.2025.26.5.1491

Neha Malviya, Anam Khan, Ananyan Sampath, Sonu Singh Ahirwar, Jagat Rakesh Kanwar, Ashwin Kotnis

{"title":"Survivin (BIRC5) Gene Polymorphism (rs9904341) Is Associated with Cancer Risk: A Meta-Analysis.","authors":"Neha Malviya, Anam Khan, Ananyan Sampath, Sonu Singh Ahirwar, Jagat Rakesh Kanwar, Ashwin Kotnis","doi":"10.31557/APJCP.2025.26.5.1491","DOIUrl":null,"url":null,"abstract":"Introduction: Survivin (BIRC5) is an anti-apoptosis protein over expressed in most cancers and associated with poor clinical outcomes. We have provided an updated meta-analysis of -31G/C (rs9904341) gene polymorphism which is highly associated with cancer risk.Methodology: A comprehensive literature search in PubMed and Google Scholar databases was conducted. A total of 10472 cases and 12193 controls from 51 studies were included in this meta-analysis. This study was prospectively registered in PROSPERO, and sensitivity analysis, risk of bias analysis, and statistical analysis were performed. A pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to assess the strength of the association. All analyses were achieved using RevMan 5.4 software and Excel 2013 version.Results: The overall meta-analysis indicates that survivin gene polymorphism -31G/C (rs9904341) is highly associated with overall cancer risk in allelic (C vs. G, OR=1.25,95% CI= 1.15 to 1.37, P<0.00001), homozygous co-dominant (CC vs. GG, OR=1.53, 95% CI= 1.23 to 1.90, P=0.0001), heterozygous co-dominant (CC vs. CG, OR= 1.34, 95% CI= 1.18 to 1.52, P<0.00001), dominant model(CC+CG vs. GG, OR= 1.29, 95% CI= 1.14 to 1.46, P= <0.0001) and recessive model (CG+GG vs. CC, OR= 0.70, 95% CI= 0.61 to 0.81, P<0.00001). The stratified analysis revealed that the variant significantly increases the risk in the Asian population.Conclusion: -31G/C (rs9904341) polymorphism of the BIRC5 gene is associated with the risk of cancer in the Asian population. However, further large-scale clinical studies are required to re-evaluate this result in the future.","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 5","pages":"1491-1505"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.5.1491","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Survivin (BIRC5) is an anti-apoptosis protein over expressed in most cancers and associated with poor clinical outcomes. We have provided an updated meta-analysis of -31G/C (rs9904341) gene polymorphism which is highly associated with cancer risk.

Methodology: A comprehensive literature search in PubMed and Google Scholar databases was conducted. A total of 10472 cases and 12193 controls from 51 studies were included in this meta-analysis. This study was prospectively registered in PROSPERO, and sensitivity analysis, risk of bias analysis, and statistical analysis were performed. A pooled odds ratio (OR) with 95% confidence interval (CI) was calculated to assess the strength of the association. All analyses were achieved using RevMan 5.4 software and Excel 2013 version.

Results: The overall meta-analysis indicates that survivin gene polymorphism -31G/C (rs9904341) is highly associated with overall cancer risk in allelic (C vs. G, OR=1.25,95% CI= 1.15 to 1.37, P<0.00001), homozygous co-dominant (CC vs. GG, OR=1.53, 95% CI= 1.23 to 1.90, P=0.0001), heterozygous co-dominant (CC vs. CG, OR= 1.34, 95% CI= 1.18 to 1.52, P<0.00001), dominant model(CC+CG vs. GG, OR= 1.29, 95% CI= 1.14 to 1.46, P= <0.0001) and recessive model (CG+GG vs. CC, OR= 0.70, 95% CI= 0.61 to 0.81, P<0.00001). The stratified analysis revealed that the variant significantly increases the risk in the Asian population.

Conclusion: -31G/C (rs9904341) polymorphism of the BIRC5 gene is associated with the risk of cancer in the Asian population. However, further large-scale clinical studies are required to re-evaluate this result in the future.

查看原文本刊更多论文

Survivin （BIRC5）基因多态性（rs9904341）与癌症风险相关：一项荟萃分析

Survivin （BIRC5）是一种在大多数癌症中过表达的抗细胞凋亡蛋白，与较差的临床结果相关。我们提供了与癌症风险高度相关的-31G/C （rs9904341）基因多态性的最新荟萃分析。方法：在PubMed和谷歌Scholar数据库中进行全面的文献检索。本荟萃分析共纳入51项研究的10472例病例和12193例对照。本研究在PROSPERO中进行前瞻性登记，并进行敏感性分析、偏倚风险分析和统计学分析。计算具有95%置信区间（CI）的合并优势比（OR）来评估相关性的强度。所有分析均使用RevMan 5.4软件和Excel 2013版本完成。结果：总体荟萃分析显示，survivin基因多态性-31G/C （rs9904341）与等位基因总体癌症风险高度相关（C vs. G， OR=1.25,95% CI= 1.15 ~ 1.37, p）。结论：BIRC5基因-31G/C （rs9904341）多态性与亚洲人群癌症风险相关。然而，未来需要进一步的大规模临床研究来重新评估这一结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Asian Pacific Journal of Cancer Prevention 医学-肿瘤学

CiteScore

2.80

自引率

0.00%

发文量

779

审稿时长

3 months

期刊介绍： Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.